Olmetab Plus
Generic Name
Olmesartan Medoxomil + Hydrochlorothiazide
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| olmetab plus 40 mg tablet | ৳ 12.00 | ৳ 120.00 |
Description
Overview of the medicine
Olmetab Plus 40 mg Tablet is a combination medicine used to treat high blood pressure (hypertension). It contains Olmesartan Medoxomil, an Angiotensin II Receptor Blocker (ARB), and Hydrochlorothiazide, a thiazide diuretic, which work together to effectively lower blood pressure.
Uses & Indications
Dosage
Adults
Usually, one tablet (Olmesartan 40 mg / Hydrochlorothiazide 12.5 mg) once daily. Dosage should be individualized based on the patient’s blood pressure response.
Elderly
No dosage adjustment is generally required, but close monitoring of renal function is recommended. Start with a lower dose if necessary.
Renal_impairment
Dose adjustment may be necessary for patients with mild to moderate renal impairment. Contraindicated in severe renal impairment (creatinine clearance < 30 mL/min).
How to Take
Take orally once daily, with or without food. Swallow the tablet whole with water. It is advisable to take it at the same time each day to help remember doses.
Mechanism of Action
Olmesartan blocks the action of angiotensin II, a natural substance that constricts blood vessels, thus relaxing them and lowering blood pressure. Hydrochlorothiazide is a diuretic that helps the body get rid of excess salt and water, further reducing blood pressure.
Pharmacokinetics
Onset
The antihypertensive effect typically begins within 2 hours for hydrochlorothiazide; peak blood pressure reduction for olmesartan is usually achieved within 2 weeks.
Excretion
Olmesartan is eliminated via both hepatic/biliary excretion (50-60%) and renal excretion (30-40%). Hydrochlorothiazide is primarily excreted unchanged by the kidneys.
Half life
Olmesartan: approximately 13 hours. Hydrochlorothiazide: 5.8 to 14.8 hours.
Absorption
Olmesartan medoxomil is a prodrug that is rapidly and completely hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Hydrochlorothiazide is well absorbed after oral administration.
Metabolism
Olmesartan is minimally metabolized in the liver to inactive metabolites. Hydrochlorothiazide is not metabolized but is rapidly eliminated by the kidney.
Side Effects
Contraindications
- •Anuria (absence of urine production)
- •Hypersensitivity to olmesartan, hydrochlorothiazide, or any sulfonylamide-derived drugs
- •Severe renal impairment (creatinine clearance < 30 mL/min)
- •Severe hepatic impairment, biliary obstruction
- •Pregnancy (second and third trimesters)
- •Concomitant use with aliskiren in patients with diabetes or renal impairment (GFR < 60 mL/min/1.73 m²)
Drug Interactions
Lithium
Increased serum lithium concentrations and lithium toxicity. Monitor lithium levels.
Corticosteroids
May enhance electrolyte depletion, particularly hypokalemia.
Digitalis glycosides
Increased risk of digitalis toxicity with hypokalemia.
Alcohol, barbiturates, narcotics
May potentiate orthostatic hypotension.
NSAIDs (e.g., ibuprofen, naproxen)
May reduce the antihypertensive effect and increase the risk of renal impairment. Monitor blood pressure and renal function.
Cholestyramine and Colestipol resins
May impair absorption of hydrochlorothiazide.
Antidiabetic drugs (oral agents and insulin)
Dosage adjustment of antidiabetic drugs may be required.
Potassium-sparing diuretics/Potassium supplements
Increased risk of hyperkalemia. Avoid concomitant use.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include hypotension, tachycardia, bradycardia, electrolyte imbalances (e.g., hypokalemia, hyponatremia), dehydration. Treatment is symptomatic and supportive, including close monitoring of blood pressure, fluid and electrolyte status.
Pregnancy & Lactation
Contraindicated during the second and third trimesters of pregnancy due to risk of fetal harm. Not recommended during breastfeeding due to potential excretion into breast milk and adverse effects on the infant.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 to 36 months from manufacturing date
Availability
Available in pharmacies
Approval Status
Approved
Patent Status
Generic versions available, likely off-patent
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in